Malcolm K. Brenner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Malcolm K. Brenner has a total of 275 co-authors. Here are the top co-authors by number of shared publications:
- Ann M. Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, and the Methodist Hospital
16 shared publications - Norihiro Watanabe
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, Texas, USA
16 shared publications - Juan F. Vera
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas
15 shared publications Sujita Sukumaran
15 shared publications- Helen E. Heslop
Baylor College of Medicine
14 shared publications Kanchana Raja
14 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Selective enrichment process of CAR- and CAR+ transgenic sub-populations
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Selective enrichment process of CAR- and CAR+ transgenic sub-populations
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure Legends from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Figure legends for Supplemental Figures 1-6 and Supplemental Table 1
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure Legends from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Figure legends for Supplemental Figures 1-6 and Supplemental Table 1
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Selective enrichment process of CAR- and CAR+ transgenic sub-populations
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Selective enrichment process of CAR- and CAR+ transgenic sub-populations
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Consolidated supplementary tables for nanostring data
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Consolidated supplementary tables for nanostring data